International Commercial Partnership
Orchid Pharma Signs Licensing & Supply Agreement with Pharmasyntez to Commercialize Exblifep® in Russia
NSE
orchpharma
BSE
524372
Orchid Pharma Limited has entered into a licensing and supply agreement with Pharmasyntez JSC, Russia, for the commercialization of Exblifep® (cefepime/enmetazobactam) in Russia. Under the agreement, Pharmasyntez will obtain exclusive rights to register and commercialize the antibiotic in Russia, while Orchid Pharma will supply the finished dosage form. The partnership represents an estimated USD 178 million opportunity over the first 10 years, subject to regulatory approvals in Russia.
PRICE-SENSITIVE TRIGGER
Event: Signing of a licensing and supply agreement with Pharmasyntez JSC for commercialization of Exblifep® in Russia.
Type: International Commercial Partnership
Impact: Positive
Immediate Effect: The agreement expands Orchid Pharma’s international commercialization strategy by providing exclusive market access for Exblifep® in Russia through a local pharmaceutical partner, subject to approval from the Russian Ministry of Health.
Commercial Metrics:
- Estimated Partnership Opportunity: Approximately USD 178 million
- Opportunity Period: First 10 years
- Commercial Model: Orchid Pharma to supply finished dosage forms while Pharmasyntez manages registration and commercialization in Russia.
Highlight:
- The agreement provides Orchid Pharma with an estimated USD 178 million commercial opportunity over the first decade, reflecting the sizeable hospital procurement market and unmet clinical demand in Russia.
What Happened ?
Orchid Pharma Limited announced that it has entered into a licensing and supply agreement with Pharmasyntez JSC, one of Russia’s pharmaceutical companies, to commercialize Exblifep® (cefepime/enmetazobactam) in the Russian market.
Exblifep® is a novel combination antibiotic developed for treating complicated urinary tract infections (cUTI) and hospital-acquired/ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram-negative bacterial pathogens.
Under the agreement, Pharmasyntez will receive exclusive rights to register and commercialize the product in Russia, while Orchid Pharma will manufacture and supply the finished dosage form. Commercialization remains subject to regulatory approval by the Ministry of Health of the Russian Federation.
Key Details
Product Overview:
- Exblifep® combines cefepime and enmetazobactam.
- Designed as a carbapenem-sparing antibiotic.
- Targets infections caused by ESBL-producing Gram-negative bacteria.
- Intended for treatment of:
- Complicated urinary tract infections (cUTI).
- Hospital-acquired bacterial pneumonia (HAP).
- Ventilator-associated bacterial pneumonia (VAP).
Regulatory Position:
- Approved by the U.S. Food and Drug Administration (FDA).
- Approved by the European Medicines Agency (EMA).
- Included in IDSA and EUCAST treatment guidelines.
- Recognized as the first new chemical entity originating from an Indian pharmaceutical company to receive approvals from both the US FDA and EMA.
Commercial Agreement:
- Pharmasyntez will have exclusive commercialization rights in Russia.
- Orchid Pharma will manufacture and supply the finished dosage form.
- Commercial launch remains subject to approval by Russian health authorities.
Strategic Importance:
- Expands Orchid Pharma’s international presence in the anti-infective segment.
- Addresses growing antimicrobial resistance in hospital settings.
- Provides access to Russia’s large hospital procurement market through an established local partner.
- Supports long-term monetization of Orchid Pharma’s proprietary antibiotic portfolio.
Note:
- The company has not disclosed financial terms such as milestone payments, royalty structure, pricing arrangements, or annual revenue guidance related to the agreement.
Risk Analysis
Summary:
- While the agreement significantly strengthens Orchid Pharma’s international commercialization pipeline, its success depends on regulatory approval, successful market registration, and future commercial adoption within Russia.
Key Risks:
- Regulatory approval from the Russian Ministry of Health is pending.
- Commercial success depends on hospital procurement and physician adoption.
- Geopolitical and regulatory developments may affect commercialization timelines.
- No detailed revenue recognition schedule has been disclosed.
Worst Case:
- Delays or rejection of regulatory approvals, slower-than-expected commercialization, or weaker market adoption could reduce the projected commercial opportunity.
Risk Level: Medium
Company Commentary
- Orchid Pharma described the partnership as an important milestone in making Exblifep® available to patients in Russia.
- Management stated that Pharmasyntez’s established reach within Russia’s hospital procurement system makes it a strong commercialization partner.
- Pharmasyntez highlighted the growing global challenge of antimicrobial resistance and noted that the agreement will help improve patient access to modern antibacterial therapy in Russia.
- Orchid Pharma reaffirmed its focus on developing innovative antibiotics addressing critical unmet medical needs.
Official Exchange Filing: Orchid Pharma Limited
